The promising pharma company ended the year on a sour note, but is still positioned for long-term...

The market's recent panic may be providing opportunities in this notoriously difficult sector.

Investors have been waiting patiently for some important updates expected at a key medical confer...

You could miss out on market-beating returns if you don't have these top stocks in your portfolio.

These biotech upstarts have deep pockets and late-stage pipelines that could make them savvy buys.

Shares of these biotechs could surge following presentations at an important medical conference.

Sometimes great stocks come in small packages.

Mr. Market thinks the double-digit slide from July was overdone. He may be right.

The pharma company saw its share price adjusted after a huge gain at the end of June.

Can these high-flying biotech stocks keep up their momentum?

Data for the company's most advanced clinical-stage drug sets the stage for a filing for FDA appr...

Shares drop after the company's first-quarter earnings results came up short of expectations.

Acceleron Pharma, Cellectis SA, and Amicus Therapeutics' shares are surging higher during the pas...

Acceleron Pharma, bluebird bio, and Sarepta Therapeutics are three rare disease specialists with ...

Insys Therapeutics, Achillion Pharmaceuticals, Portola Pharmaceuticals, Ophthotech, and Acceleron...

The Dow finished just below its all-time highs, but the market's overall gains were small compare...

Stocks ended the year on a positive note, with the Dow and S&P 500 both climbing to all-time reco...